Ó£»¨ÊÓƵ

Skip to main content

TableÌý2 Comparison of baseline characteristics between PROMISE-EPI participants interviewed and non-interviewed, Lusaka, Zambia

From: Barriers and facilitators of a large clinical trial on prevention of HIV transmission through breastfeeding in Lusaka, Zambia: a qualitative study

Ìý

PROMISE-EPI participants interviewed

PROMISE-EPI participants not interviewed

P value

N = 80a

N = 1262

Intervention arm

Ìý

49 (61.3%)

619 (49%)

0.038

Mothers

â€Çã²µ±ð

mean (sd)

30.0 (6.5)

30.5 (5.9)

0.47

 Time of HIV diagnosis

Before this last pregnancy

53 (66.3%)

899/1260 (71.3%)

0.37

During/after this last pregnancy

27 (33.8%)

361/1260 (28.7%)

Ìý

Mothers taking ART

Ìý

76 (95.0%)

1243 (98.5%)

0.044

 Highest level of education

None

5 (6.3%)

82 (6.5%)

0.87

Primary

29 (36.3%)

494 (39.1%)

Ìý

Secondary or more

46 (57.5%)

686 (54.4%)

Ìý

 Employment situation during pregnancy

Not working

56 (70.0%)

872 (69.1%)

0.61

Working (formal sector)

5 (6.3%)

122 (9.7%)

Ìý

Working (informal sector)

17 (21.3%)

248 (19.7%)

Ìý

Studying

2 (2.5%)

20 (1.6%)

Ìý

 Marital status

Married/cohabitating

63 (78.8%)

1,047 (83.0%)

0.43

Single

15 (18.8%)

173 (13.7%)

Ìý

Divorced/separate/widowed

2 (2.5%)

42 (3.3%)

Ìý

 HIV Status known by partner

No

7/71 (9.9%)

88/974 (9.0%)

0.29

Yes

60/71 (84.5%)

858/974 (88.1%)

Ìý

Not applicable (no partner)

4/71 (5.6%)

28/974 (2.9%)

Ìý

 Maternal VL > = 1000cp/mL at EPI-2 (both arms)

38 (47.5%)

105/1222 (8.6%)

&±ô³Ù; 0.001

 Maternal VL > = 1000cp/mL at M6

23/76 (30.3%)

64/1054 (6.1%)

&±ô³Ù; 0.001

 Still breastfeeding at M12

63/79 (79.7%)

734/990 (74.1%)

0.35

Infants

â€Çȱð³æ

Female

40 (50.0%)

611 (48.4%)

0.82

 Six week PNP at birth (3 drugs)

74 (92.5%)

1217/1262 (96.4%)

0.12

 Infant eligible to lamivudine at EPI-2 (intervention arm)

35 (43.8%)

37 (2.9%)

&±ô³Ù; 0.001

 Newly eligible to lamivudine at M6 (mother on the intervention arm newly unsuppressed)

3 (3.8%)

13 (1.0%)

0.065

  1. ART Antiretroviral therapy, VL Viral load, PNP Post-natal-prophylaxis, EPI-2 second visit of the expanded program on immunization
  2. a The PROMISE-EPI identifier was not recorded for one PROMISE-EPI participant